Published in Law and Health Weekly, May 1st, 2004
In addition, Altor has been awarded a Small Business Innovation Research (SBIR) grant to support development of STAR reagents for tumor diagnostic applications.
The report entitled "A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity" appears in the April issue of Cancer Immunology, Immunotherapy. In these studies, Altor generated functional STAR fusion...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.